Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions
This article was originally published in The Tan Sheet
Executive Summary
Merck should conduct a head-to-head comparison study of Mevacor use in prescription and over-the-counter settings, Endocrinologic & Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for lovastatin 10 mg.